P3 - Target Discovery In Sarcoma Through Gemone-Wide Genetic and Functional Anal

$276,896P50FY2010CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications & trials

Paper 38182785 Paper 37943631 Paper 37598656 Paper 37477937 Paper 36376999 Paper 35848761 Paper 35771370 Paper 35766997 Paper 35763541 Paper 35753087 Paper 35672279 Paper 35665561 Paper 35575789 Paper 35521817 Paper 35521683 Paper 35443099 Paper 35430756 Paper 35429182 Paper 35347249 Paper 35256598 Paper 35170141 Paper 35168293 Paper 35120664 Paper 35110418 Paper 34965948 Paper 34958509 Paper 34907995 Paper 34862698 Paper 34791601 Paper 34755412 Paper 34747541 Paper 34667024 Paper 34651371 Paper 34503977 Paper 34398495 Paper 34391056 Paper 34313371 Paper 34310785 Paper 34269943 Paper 34193943 Paper 34165212 Paper 34131293 Paper 33999553 Paper 33987888 Paper 33899786 Paper 33859361 Paper 33649458 Paper 33632930 Paper 33574497 Paper 33455033 Paper 33402214 Paper 33399341 Paper 33382123 Paper 33318580 Paper 33288675 Paper 33283135 Paper 33229459 Paper 33073343 Paper 33034932 Paper 33024275 Paper 32991341 Paper 32770123 Paper 32641862 Paper 32604167 Paper 32557980 Paper 32511981 Paper 32509759 Paper 32372022 Paper 32362012 Paper 32161142 Paper 32034283 Paper 31994243 Paper 31972596 Paper 31934916 Paper 31756779 Paper 31675134 Paper 31595587 Paper 31592798 Paper 31589790 Paper 31567194 Paper 31537895 Paper 31478943 Paper 31464709 Paper 31448442 Paper 31433528 Paper 31283560 Paper 31219820 Paper 31213500 Paper 31135487 Paper 31112350 Paper 31008539 Paper 30920708 Paper 30864973 Paper 30829727 Paper 30720533 Paper 30706225 Paper 30610557 Paper 30550870 Paper 30418203 Paper 30276917

Abstract

Our overall goal is a compreiiensive molecular genetic and functional analysis of two of the most common soft tissue sarcomas, myxofibrosarcoma (MYXF) and pleomorphic malignant fibrous histiocytoma (PMFH), so as to elucidate the mutational programs and pathways involved in sarcomagenesis and to identify novel therapeutic targets. Tissue samples and cell lines of MYXF and PMFH will be subjected to a multiplatform genome-wide characterization of expression of protein-coding genes and microRNAs, DNA copy number changes, activating mutations, and gene rearrangements. These data will be used to identify both genetically distinct subtypes of MYXF and PMFH and molecular signatures associated with tumor morphology, grade, recurrence, and survival. To identify potential therapeutic targets, we will screen the genes and microRNAs in these signatures for involvement in proliferation, differentiation, and survival of MYXF and PMFH cell lines. Potential targets will be validated by functional assays in additional cell lines and in xenografts. To achieve these goals, we have assembled a multidisciplinary group of investigators armed with 2 unique resources: a database of prospectively collected clinical-pathologic and outcomes data on over 8300 patients treated for soft tissue sarcoma at MSKCC, and a linl<ed tissue banl<with over 5500 sarcoma samples and 68 primary sarcoma cell lines. The highly interactive and synergistic collaboration between MSKCC and Rocl<efeller will ensure maximum productivity in molecular target identification. The comprehensive information generated will facilitate the development of new subtype-specific targeted therapies for MYXF and PMFH.

View original record on NIH RePORTER →